On February 27, 2017, Cellular Biomedicine Group, Inc. (the “Company”) issued a press release announcing that it has been awarded a $2.29 million grant from the California Institution for Regenerative Medicine to support the Company’s pre-clinical studies of stem cell therapy for treating Knee Osteoarthritis. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

99.1 Press Release, dated February 27, 2017

About CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG)

Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.

CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Recent Trading Information

CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) closed its last trading session 00.00 at 11.50 with 17,228 shares trading hands.